Arcus Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Arcus Biosciences has a total shareholder equity of $707.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.3B and $586.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$995.00m |
| Equity | US$707.00m |
| Total liabilities | US$586.00m |
| Total assets | US$1.29b |
Recent financial health updates
Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money
May 10
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Mar 20Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?
Nov 30Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation
Aug 08Recent updates
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO
May 15Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts
May 13Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money
May 10We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Mar 20What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You
Feb 23Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment
Feb 22Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Dec 18Arcus Biosciences: Showing There Might Be Something To TIGIT After All
Dec 15Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?
Nov 30Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey
Nov 20Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
Aug 29Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation
Aug 08Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates
Jun 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk
May 05Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17
Nov 02Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers
May 12Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add
Jan 07Forecast: Analysts Think Arcus Biosciences, Inc.'s (NYSE:RCUS) Business Prospects Have Improved Drastically
Nov 25Financial Position Analysis
Short Term Liabilities: RCUS's short term assets ($1.1B) exceed its short term liabilities ($204.0M).
Long Term Liabilities: RCUS's short term assets ($1.1B) exceed its long term liabilities ($382.0M).
Debt to Equity History and Analysis
Debt Level: RCUS is debt free.
Reducing Debt: RCUS has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RCUS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: RCUS has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 5.7% each year